Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 4Stomach Neoplasms 3Peptic Ulcer 2Gastritis 2Dyspepsia 2Recurrence 1Lymphoma, B-Cell, Marginal Zone 1Helicobacter Infections 1Chemotherapy Effect 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 15Carboplatin 9liposomal doxorubicin 8Bevacizumab 8pembrolizumab 7Topotecan 6olaparib 4mirvetuximab soravtansine 4Nivolumab 4Cyclophosphamide 4niraparib 3fludarabine 3Gemcitabine 3Drug Therapy 3rucaparib 2ribociclib 2pegfilgrastim 2palbociclib 2oregovomab 2fludarabine phosphate 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 21-dodecylpyridoxal 2trastuzumab deruxtecan 1sacituzumab govitecan 1isoquercitrin 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Clarithromycin × 1 year × Clear all
NCT07341100 2026-06-01

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡